Table 2 Quality assessment of vaccine trials for immunization against 鈥� Shigella
From: Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus
| 听 | Quality Assessment | Summary of Findings | ||||||
|---|---|---|---|---|---|---|---|---|
| 听 | 听 | 听 | 听 | Directness | No of events | 听 | ||
No of Studies | Design | Limitations | Consistency | Generalizability to population of interest | Generalizability to intervention of interest | Intervention | Control | Risk Ratio |
Efficacy against morbidity, Shigella Infection (S.Flexneri): Low-outcome-specific quality | ||||||||
RCT | Random effect model. Insignificant results | Two studies show consistent benefit | Two studies were from developed countries | Two used oral vaccine while one used intramuscular | 56 | 107 | 0.72 (0.37, 1.39)b | |
RCT | Random effect model. Insignificant results | One study shows significant benefit | One study from developed country | Oral Vaccines | 49 | 99 | 0.67 [0.28, 1.59]b | |
01 [40] | RCT | Only one study | 听 | Study was conducted in Israel | Parenteral Vaccine | 07 | 08 | 0.92 [0.33, 2.53] |
Efficacy against morbidity, Shigella Infection (S.Sonnei): Low-outcome-specific quality | ||||||||
RCT | Random effect model. Insignificant results | Two studies show consistent benefit | Two studies were from developed countries | Two used oral vaccine while one used intramuscular | 39 | 94 | 0.47 (0.12, 1.85)b | |
RCT | Random effect model. Insignificant results | One study shows significant benefit | One study from developed country | Oral Vaccines | 10 | 56 | 0.39 [0.04, 4.33]b | |
01 [40] | RCT | Only one study | 听 | Study was conducted in Israel | Parenteral Vaccines | 29 | 38 | 0.73 [0.45, 1.17] |
One or more Adverse events (S.Flexneri): Low outcome-specific quality | ||||||||
RCT | None | inconsistent results | Both from developing countries | 听 | 45 | 08 | 1.58(0.81, 3.07)a | |